Literature DB >> 23059459

Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.

Lucy M Hinder1, Andrea M Vincent, John M Hayes, Lisa L McLean, Eva L Feldman.   

Abstract

Dyslipidemia has been identified as an important pathogenic risk factor for diabetic neuropathy, but current animal models do not adequately reproduce the lipid profile observed in human diabetics (increased triglycerides with an elevated LDL-cholesterol and reduced HDL-cholesterol). High fat feeding of mice produces hyperlipidemia, but mice are resistant to increases in the LDL to HDL ratio, reducing the potential for peripheral lipid deposits to impact neuropathy, as is postulated to occur in human subjects. Genetic manipulations provide an alternative approach to reproducing a neuropathic plasma lipid profile. Based on findings from the atherosclerosis literature, we began with knockout of ApoE. Since knockout of ApoE alone only partially mimics the human diabetic lipid profile, we examined the impact of its combination with a well-characterized model of type 2 diabetes exhibiting neuropathy, the db/db mouse. We added further gene manipulations to increase hyperlipidemia by using mice with both ApoE and ApoB48 knockout on the ob/+ (leptin mutation) mice. In all of these models, we found that either the db/db or ob/ob genotypes had increased body weight, hyperlipidemia, hyperglycemia, and evidence of neuropathy compared with the control groups (db/+ or ob/+, respectively). We found that ApoE knockout combined with leptin receptor knockout produced a lipid profile most closely modeling human dyslipidemia that promotes neuropathy. ApoE knockout combined with additional ApoB48 and leptin knockout produced similar changes of smaller magnitude, but, notably, an increase in HDL-cholesterol. Our data suggest that the overall effects of ApoE knockout, either directly upon nerve structure and function or indirectly on lipid metabolism, are insufficient to significantly alter the course of diabetic neuropathy. Although these models ultimately do not deliver optimal lipid profiles for translational diabetic neuropathy research, they do present glycemic and lipid profile properties of value for future therapeutic investigations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23059459      PMCID: PMC3534788          DOI: 10.1016/j.expneurol.2012.10.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  35 in total

1.  The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes.

Authors:  B Isomaa; M Henricsson; P Almgren; T Tuomi; M R Taskinen; L Groop
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

Review 2.  Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism.

Authors:  J Poirier
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 3.  Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines.

Authors:  A Clemens; E Siegel; B Gallwitz
Journal:  Exp Clin Endocrinol Diabetes       Date:  2004-10       Impact factor: 2.949

4.  The effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice.

Authors:  Sang Su Oh; John M Hayes; Catrina Sims-Robinson; Kelli A Sullivan; Eva L Feldman
Journal:  Neurosci Lett       Date:  2010-08-05       Impact factor: 3.046

5.  The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia.

Authors:  Moriz Buzello; Johannes Törnig; Jörg Faulhaber; Heimo Ehmke; Eberhard Ritz; Kerstin Amann
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

6.  Effect of hyperglycemia on pain threshold in alloxan-diabetic rats.

Authors:  Jana Herrman Lee; Daniel J Cox; Douglas G Mook; Richard C McCarty
Journal:  Pain       Date:  1990-01       Impact factor: 6.961

Review 7.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

8.  Altered HDL subclasses in endogenous hypertriglyceridemia are not affected by weight reduction.

Authors:  B Gonen; W Patsch; I Kuisk; A Goldberg; R Phair; G Schonfeld
Journal:  Metabolism       Date:  1985-05       Impact factor: 8.694

9.  [Effect of trapidil on neuropathy in diabetic mice].

Authors:  H Inaba; K Kato; T Yano
Journal:  Nihon Yakurigaku Zasshi       Date:  1986-08

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  18 in total

1.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.

Authors:  Lucy M Hinder; Claudia Figueroa-Romero; Crystal Pacut; Yu Hong; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2013-10-05       Impact factor: 8.401

Review 2.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

3.  A leptin-regulated circuit controls glucose mobilization during noxious stimuli.

Authors:  Jonathan N Flak; Deanna Arble; Warren Pan; Christa Patterson; Thomas Lanigan; Paulette B Goforth; Jamie Sacksner; Maja Joosten; Donald A Morgan; Margaret B Allison; John Hayes; Eva Feldman; Randy J Seeley; David P Olson; Kamal Rahmouni; Martin G Myers
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 4.  Mouse models of diabetic neuropathy.

Authors:  Phillipe D O'Brien; Stacey A Sakowski; Eva L Feldman
Journal:  ILAR J       Date:  2014

5.  Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.

Authors:  Marta Soltesova Prnova; Lucia Kovacikova; Karol Svik; Stefan Bezek; Zübeyir Elmazoğlu; Cimen Karasu; Milan Stefek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-05       Impact factor: 3.000

6.  Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying.

Authors:  Seiichiro Fukuhara; Tatsuhiro Masaoka; Soraya Nishimura; Masaya Nakamura; Juntaro Matsuzaki; Hitoshi Tsugawa; Sawako Miyoshi; Hideki Mori; Satoshi Kawase; Shinsuke Shibata; Hideyuki Okano; Takanori Kanai; Hidekazu Suzuki
Journal:  Dig Dis Sci       Date:  2017-11-02       Impact factor: 3.199

7.  Endometriosis promotes atherosclerosis in a murine model.

Authors:  Ramanaiah Mamillapalli; Nikoletta Toffoloni; Shutaro Habata; Huang Qunhua; Rula Atwani; Nina Stachenfeld; Hugh S Taylor
Journal:  Am J Obstet Gynecol       Date:  2022-03-26       Impact factor: 10.693

8.  The role of endoplasmic reticulum stress in hippocampal insulin resistance.

Authors:  Catrina Sims-Robinson; Anna Bakeman; Rebecca Glasser; Janet Boggs; Crystal Pacut; Eva L Feldman
Journal:  Exp Neurol       Date:  2016-01-13       Impact factor: 5.330

9.  Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy.

Authors:  Jiacheng Ma; Kevin L Farmer; Pan Pan; Michael J Urban; Huiping Zhao; Brian S J Blagg; Rick T Dobrowsky
Journal:  J Pharmacol Exp Ther       Date:  2013-11-21       Impact factor: 4.030

Review 10.  Identifying Common Genetic Risk Factors of Diabetic Neuropathies.

Authors:  Ini-Isabée Witzel; Herbert F Jelinek; Kinda Khalaf; Sungmun Lee; Ahsan H Khandoker; Habiba Alsafar
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.